TANDEM DIABETES CARE INC(TNDM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,998 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TNDM Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for TANDEM DIABETES CARE INC (TNDM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TNDM at 42.8/100 on a 32-signal composite quality model, placing it at rank #1,998 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include free cash flow (22.8) and balance sheet strength (23.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TANDEM DIABETES CARE INC reports quarterly revenue of $254.6M, net income of $-21.2M, an operating margin of -5.4%. Top institutional holders of TNDM by reported 13-F value include BlackRock, UBS Group AG, Sessa Capital IM, L.P., based on the most recent SEC filings. TNDM trades on the Nasdaq exchange and files with the SEC under CIK 1438133. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TNDM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TANDEM DIABETES CARE INC directly from SEC EDGAR. TANDEM DIABETES CARE INC's 13F Pro composite quality score has ranged between 27 and 54 since 2021, currently 42.8 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.
Revenue
Q2 2026
$254.6M
Net Income
Q2 2026
$-21.2M
Free Cash Flow
Q2 2026
$-38.7M
Operating Margin
Q2 2026
-5.4%
ROIC
Q2 2026
-7.5%
D/E Ratio
Q2 2026
4.62
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+7.9% YoYNet Income
-113.2% YoYOperating Income
-88.9% YoYEPS (Diluted)
-106.8% YoYTotal Assets
-8.9% YoYTotal Debt
-11.1% YoYOp. Cash Flow
-140.1% YoYFree Cash Flow
-694.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.01B +7.9% | $940.2M +25.7% | $747.7M -6.7% | $801.2M +14.0% | $702.8M +40.9% | $498.8M |
| Net Income | $-204.7M -113.2% | $-96.0M +56.9% | $-222.6M -135.3% | $-94.6M -707.7% | $15.6M +145.3% | $-34.4M |
| Operating Income | $-187.3M -88.9% | $-99.1M +57.5% | $-233.2M -151.2% | $-92.8M -509.9% | $22.7M +384.7% | $-8.0M |
| EPS (Diluted) | $-3.04 -106.8% | $-1.47 +57.1% | $-3.43 -133.3% | $-1.47 -712.5% | $0.24 +142.9% | $-0.56 |
| Total Assets | $881.1M -8.9% | $967.7M +1.6% | $952.7M -9.5% | $1.05B +16.3% | $905.1M +26.3% | $716.4M |
| Total Debt | $310.0M -11.1% | $348.9M +22.4% | $285.0M | — | — | — |
| Operating Cash Flow | $-9.7M -140.1% | $24.2M +176.2% | $-31.8M -163.0% | $50.5M -54.7% | $111.4M +351.4% | $24.7M |
| Free Cash Flow | $-29.7M -694.1% | $5.0M +108.5% | $-58.6M -458.1% | $16.4M -83.2% | $97.2M +3648.0% | $-2.7M |
Get alerted when TNDM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for TANDEM DIABETES CARE INC including:
Top Institutional Holders of TNDM
BlackRock, Inc.
$174.8M11,583,125 shUBS Group AG
$78.1M5,178,570 shSessa Capital IM, L.P.
$77.0M5,100,000 shLINDEN ADVISORS LP
$71.2M74,791,000 shVANGUARD PORTFOLIO MANAGEMENT LLC
$64.9M4,299,667 shFirst Light Asset Management, LLC
$51.1M3,383,553 shVANGUARD CAPITAL MANAGEMENT LLC
$46.7M3,096,536 shSTATE STREET CORP
$43.0M2,851,646 shBANK OF MONTREAL /CAN/
$40.0M42,039,000 shGW&K Investment Management, LLC
$38.8M2,569,032 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $174.8M | 11,583,125 |
| UBS Group AG | $78.1M | 5,178,570 |
| Sessa Capital IM, L.P. | $77.0M | 5,100,000 |
| LINDEN ADVISORS LP | $71.2M | 74,791,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $64.9M | 4,299,667 |
| First Light Asset Management, LLC | $51.1M | 3,383,553 |
| VANGUARD CAPITAL MANAGEMENT LLC | $46.7M | 3,096,536 |
| STATE STREET CORP | $43.0M | 2,851,646 |
| BANK OF MONTREAL /CAN/ | $40.0M | 42,039,000 |
| GW&K Investment Management, LLC | $38.8M | 2,569,032 |
Companies Similar to TNDM
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
iRhythm Holdings, Inc.
PTC THERAPEUTICS, INC.
Alphatec Holdings, Inc.
NeuroPace Inc
NovoCure Ltd
Enovis CORP
Immunocore Holdings plc
Guardant Health, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put TNDM on your watchlist
Track score changes the day TANDEM DIABETES CARE INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TNDM a good stock to buy?
13F Pro's AI-powered analysis of TANDEM DIABETES CARE INC (TNDM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TNDM are available on the TNDM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TNDM is classified as a small company.
Which hedge funds own TNDM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TNDM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TANDEM DIABETES CARE INC's investment landscape.